Reply by Authors
J Urol
.
2021 Mar;205(3):832.
doi: 10.1097/JU.0000000000001425.02.
Epub 2021 Jan 5.
Authors
Steven Rosenberg
1
,
Marc Bonten
2
,
Wouter Haazen
3
,
Bart Spiessens
3
,
Darren Abbanat
4
,
Oscar Go
4
,
Florian Wagenlehner
5
,
Neal Shore
6
,
Yosuke Hagiwara
7
,
Patricia Ibarra de Palacios
8
,
Jeroen Geurtsen
9
,
Peter Hermans
2
,
Jan Poolman
9
Affiliations
1
The Iowa Clinic, West Des Moines, Iowa.
2
Julius Center, UMC Utrecht, Utrecht, Netherlands.
3
Janssen Research & Development, Beerse, Belgium.
4
Janssen Research & Development LLC, Raritan, New Jersey.
5
Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig University, Giessen, Germany.
6
Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina.
7
Janssen Pharmaceutical K.K., Tokyo, Japan.
8
Janssen Vaccines, Bern, Switzerland.
9
Janssen Vaccines & Prevention B.V., Leiden, Netherlands.
PMID:
33403863
DOI:
10.1097/JU.0000000000001425.02
No abstract available
Publication types
Comment